Phathom Pharmaceuticals Inc (PHAT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $492.63M
Last updated: Nov 17, 2026 at 11:05 AM ET
Phathom Pharmaceuticals Inc (PHAT) Competitors
The companies most similar to Phathom Pharmaceuticals are Prothena Corporation (PRTA), X4 Pharmaceuticals (XFOR) and DiaMedica Therapeutics (DMAC). By market cap, Phathom Pharmaceuticals ranks 4th of the 13 companies on this page; Pharming Group NV (PHAR) is the largest at $891.80M. The median P/E of the 3 companies with a P/E is 39.3x.
Peer Comparison
PHAT's ROIC of 11.4% is above the peer median of -34.8%, and its revenue growth of 71.1% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| X4 Pharmaceuticals Inc (XFOR) | $318.59M | N/A | 21.7x | 0.0% | -36.9% | 63.1% | 0.00% |
| DiaMedica Therapeutics Inc (DMAC) | $474.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pharming Group NV (PHAR) | $891.80M | 39.3x | 2.4x | 6.3% | 7.9% | 20.8% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Tectonic Therapeutic, Inc. (TECX) | $413.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Puma Biotechnology Inc (PBYI) | $401.70M | 15.0x | 1.6x | 10.3% | N/A | 1.1% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| PepGen Ltd (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Fennec Pharmaceuticals Inc (FENC) | $410.25M | 159.5x | 6.8x | 3.0% | N/A | 57.3% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $416.14M | 39.3x | 7.3x | 0.0% | -34.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Phathom Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| X4 Pharmaceuticals Inc (XFOR) | X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development... | XFOR competitors |
| DiaMedica Therapeutics Inc (DMAC) | DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. | DMAC competitors |
| Pharming Group NV (PHAR) | Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States... | PHAR competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Tectonic Therapeutic, Inc. (TECX) | Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel... | TECX competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Puma Biotechnology Inc (PBYI) | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States... | PBYI competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| PepGen Ltd (PEPG) | PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious... | PEPG competitors |
| Fennec Pharmaceuticals Inc (FENC) | Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. | FENC competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
Frequently Asked Questions About PHAT
Who are Phathom Pharmaceuticals' main competitors?
The companies most similar to Phathom Pharmaceuticals include Prothena Corporation (PRTA), X4 Pharmaceuticals (XFOR), DiaMedica Therapeutics (DMAC), Pharming Group NV (PHAR) and Fulcrum Therapeutics (FULC), listed from the closest match.
Who is Phathom Pharmaceuticals' biggest competitor?
Pharming Group NV (PHAR) is the largest of the similar companies at $891.80M; Prothena Corporation (PRTA) is the closest match by business profile, size, sector and industry.
How does PHAT stock compare with its competitors?
PHAT's P/S is 1.8x against a peer median of 7.3x; its net margin is -30.2% against a peer median of 0.0%.
Which of Phathom Pharmaceuticals' competitors pays a higher dividend?
Phathom Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Phathom Pharmaceuticals bigger than its competitors?
No. Phathom Pharmaceuticals is 4th by market cap among the 13 companies on this page; the largest is Pharming Group NV (PHAR) at $891.80M.
PHAT pages: Overview, Earnings, Forecast, Financials, Competitors